Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:03 AM
Ignite Modification Date:
2025-12-25 @ 3:03 AM
NCT ID:
NCT04871633
Eligibility Criteria:
Inclusion Criteria:
1. All Patients with confirmed COVID-19 of either gender and aged 12 years and above.
2. Patients having Severe COVID 19 Disease. Severe disease is defined as patients with an oxygen saturation (SpO2) ≤94% on room air or requiring supplemental oxygen or requiring mechanical ventilation or requiring extracorporeal membrane oxygenation (ECMO).17
\-
Exclusion Criteria:
1. Known severe allergic reaction to Remdesivir or to other antiviral drugs
2. Patients already having other treatments like tocilizumab or other antiviral drugs
3. Pregnancy or breastfeeding
4. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>5 times upper normal limit
5. Creatinine clearance \<30ml/min
6. Low platelet count \<50,000/l
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
12 Years
Study:
NCT04871633
Study Brief:
Protocol Section:
NCT04871633